Hong Kong medical equipment purchaser Bao Wei Pharmaceuticals (AED.US) applies for a US stock IPO, planning to raise $7 million.

Hong Kong-based medical equipment and software procurement company Baowei Medicine (AED.US) submitted documents to the US Securities and Exchange Commission (SEC) last Thursday, planning to raise up to $7 million through an initial public offering (IPO). The company plans to issue 900,000 shares of stock at a price of $7 to $9 per share, raising $7 million. Based on the midpoint of the proposed offering range, Baowei Medicine's market value will reach $87 million. Baowei Medicine sells medical equipment and software to distributors and medical institutions in Hong Kong and mainland China through its subsidiaries. Its products include infusion pumps, anesthesia laryngoscopes, portable X-ray machines, automated external defibrillators, and a suite of self-developed medical software, including the Pre-imaging software Prim and MRI analysis software iMRIPlus. This Hong Kong-based company was founded in 2003 and recorded revenue of $25 million in the 12 months ending March 31, 2025. The company plans to list on the Nasdaq under the ticker symbol "AED." Maxim Group LLC is the exclusive underwriter for this transaction.